Bayer warns that Nexavar patent may be vulnerable to revocation
This article was originally published in Scrip
Executive Summary
Bayer has claimed that its patent for the anticancer Nexavar (sorafenib tosylate) could become ''vulnerable'' for revocation in India, since Natco Pharma, the compulsory licence holder, may not be able to meet the ''reasonable requirements'' of the public as envisaged in the landmark compulsory licensing order in March this year (www.scripintelligence.com, 12 March, 2012).